Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Petros PharmaceuticalsPTPI +20.00% 3-Year EBITDA Growth Rate is 90.00% as of Mar. 2026, which is 112% above its 10-year median of 42.50. Among 811 Drug Manufacturers companies, Petros Pharmaceuticals ranks better than 96.92% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 90.00% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 72.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Petros Pharmaceuticals was 90.00% per year. The lowest was 22.80% per year. And the median was 42.50% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Petros Pharmaceuticals 3-Year EBITDA Growth Rate Related Terms
PTPI vs KOAN, KAYS, OWPC: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Petros Pharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Petros Pharmaceuticals 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Petros Pharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Petros Pharmaceuticals's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 90.00% mean?
Petros Pharmaceuticals (PTPI) has a 3-Year EBITDA Growth Rate of 90.00% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Petros Pharmaceuticals and its competitors. This is 112% above median its historical median of 42.50. Over the past decade, Petros Pharmaceuticals' 3-Year EBITDA Growth Rate has ranged from 22.80 to 90.00. According to the industry distribution chart, Petros Pharmaceuticals ranks #25 out of 811 companies in the Drug Manufacturers industry, placing it in the top 3.1%.
Is Petros Pharmaceuticals' 3-Year EBITDA Growth Rate too high?
Petros Pharmaceuticals' current 3-Year EBITDA Growth Rate of 90.00% is 112% above median its 10-year median of 42.50. Over the past 10 years, this metric has ranged from a low of 22.80 to a high of 90.00. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.80. Petros Pharmaceuticals' value of 90.00% is 922.7% above this industry median. Based on the distribution chart, Petros Pharmaceuticals ranks #25 out of 811 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Petros Pharmaceuticals' 3-Year EBITDA Growth Rate compare to KOAN and KAYS?
According to the Drug Manufacturers industry distribution chart, Petros Pharmaceuticals ranks #25 out of 811 companies for 3-Year EBITDA Growth Rate. This places Petros Pharmaceuticals in the top 3% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.80. Petros Pharmaceuticals' value of 90.00% is 922.7% above this benchmark. Historically, Petros Pharmaceuticals' own 3-Year EBITDA Growth Rate has ranged from 22.80 to 90.00 over the past decade. While the company's 10-year median is 42.50 vs. the industry median of 8.80, Petros Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.80, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Petros Pharmaceuticals's current 3-Year EBITDA Growth Rate of 90.00% is 922.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Petros Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Petros Pharmaceuticals's current 3-Year EBITDA Growth Rate is 90.00%, which is 112% above median its own 10-year median of 42.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Petros Pharmaceuticals stock overvalued right now?
Petros Pharmaceuticals (PTPI) has a current 3-Year EBITDA Growth Rate of 90.00%. The current 3-Year EBITDA Growth Rate is 90.00%, which is 112% above median its 10-year median of 42.50 and 922.7% above the Drug Manufacturers industry median of 8.80. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Petros Pharmaceuticals (PTPI), the current 3-Year EBITDA Growth Rate is 90.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Petros Pharmaceuticals Inc is a men's health pharmaceutical company. The Company is working towards the goal of becoming an innovator in the emerging self-care market, driving expanded access to key nonprescription pharmaceuticals as Over-the-Counter and nonprescription drug products with additional conditions for nonprescription use (ACNU Products) treatment options. Petros is pursuing the development of a proprietary integrated technology solutions platform containing two components: SaaS, designed to assist pharmaceutical companies in operationalizing and commercializing an Rx-to-OTC switch as an element in the development of an ACNU Product, and a potential Software as a Medical Device component, which guides the consumer in navigating appropriate self-selection or deselection.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PTPI has been successfully added to your 
